| 194.82 1.84 (0.95%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 232.59 | 1-year : | 271.67 |
| Resists | First : | 199.13 | Second : | 232.59 |
| Pivot price | 191.03 |
|||
| Supports | First : | 178.68 |
Second : | 166.03 |
| MAs | MA(5) : | 193.64 |
MA(20) : | 190.6 |
| MA(100) : | 150.92 |
MA(250) : | 130.54 |
|
| MACD | MACD : | 5.8  |
Signal : | 6.6 |
| %K %D | K(14,3) : | 66.8 |
D(3) : | 68.1 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 199.13 | Low : | 88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ILMN ] has closed below upper band by 20.1%. Bollinger Bands are 41.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 196.86 - 197.62 | 197.62 - 198.49 |
| Low: | 187.44 - 188.24 | 188.24 - 189.16 |
| Close: | 193.3 - 194.61 | 194.61 - 196.12 |
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Wed, 29 Jul 2026
Illumina, Inc. Revenue Breakdown – NASDAQ:ILMN - TradingView
Wed, 29 Jul 2026
ILLUMINA, INC. (ILMN) names Chief Commercial Officer as insider with no holdings - Stock Titan
Wed, 29 Jul 2026
Illumina Inc (ILMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mon, 27 Jul 2026
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Mon, 27 Jul 2026
ILMN|Illumina Inc|Price:192.480|Chg%:-0.500 - TradingKey
Sat, 25 Jul 2026
Illumina, Inc. Revenue Breakdown – BIVA:ILMN - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 151 (M) |
| Shares Float | 148 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 107.1 (%) |
| Shares Short | 8,750 (K) |
| Shares Short P.Month | 9,210 (K) |
| EPS | 5.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.6 |
| Profit Margin | 19.4 % |
| Operating Margin | 18.3 % |
| Return on Assets (ttm) | 8.6 % |
| Return on Equity (ttm) | 33.8 % |
| Qtrly Rev. Growth | 4.8 % |
| Gross Profit (p.s.) | 19.82 |
| Sales Per Share | 29.01 |
| EBITDA (p.s.) | 7.66 |
| Qtrly Earnings Growth | 6 % |
| Operating Cash Flow | 1,130 (M) |
| Levered Free Cash Flow | 846 (M) |
| PE Ratio | 35.48 |
| PEG Ratio | 3.4 |
| Price to Book value | 11.06 |
| Price to Sales | 6.71 |
| Price to Cash Flow | 26.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|